Statistically Significant Is Not the Same as Clinically Important: A Peptide-Study Guide

Statistical significance asks whether an observed result would be unusual under a particular statistical model. Clinical importance asks whether the size and type of that result would matter in practice. They are different questions: a tiny effect can have a small p value, while a potentially important effect can miss a conventional significance threshold when a study is small or imprecise.

A statistical threshold and a patient-important effect are separate judgments. Study design, effect size, uncertainty, outcome choice, and clinical context all sit between them.

Quick answer: A small p value does not measure effect size, prove the research hypothesis, establish causality, or show that an outcome matters to patients. A non-significant result does not automatically prove no effect, equivalence, or safety. Read the estimate, confidence interval, absolute numbers, endpoint, analysis plan, and study design together.[^asa][^greenland]

Statistical significance vs clinical significance at a glance

| Question | Best place to look | What it can tell you | What it cannot tell you alone | |---|---|---|---| | Was the result statistically significant? | Prespecified analysis, p value, confidence interval | Whether the result crossed a defined statistical threshold under the stated model | Effect size, causality, clinical value, or truth | | How large was the observed difference? | Effect estimate | Magnitude and direction in the study | Precision, bias, or patient importance | | How uncertain is the estimate? | Confidence interval and event count | A range of values reasonably compatible with the data and method | A fixed probability that the true value lies inside this one interval | | Would the difference matter? | Absolute change, outcome importance, duration, harms, burden | Practical relevance in the studied context | Whether the estimate is unbiased or generalizable | | Was the analysis credible? | Protocol, prespecification, multiplicity plan, missing-data handling | Protection against selective analysis and chance findings | Elimination of every source of bias |

What does a p-value actually mean?

A p value is a conditional calculation: assuming the null hypothesis and the statistical model are correct, it measures how incompatible the observed data—or more extreme data—are with that setup. It is not the probability that the null hypothesis is true.

That distinction matters because several popular translations are wrong. A p value of 0.03 does not mean:

• there is a 97% chance the peptide caused the result;
• the result has a 3% chance of being due to chance;
• the research hypothesis is proven;
• the effect is large;
• the result will replicate;
• the study was free of confounding, missing-data bias, measurement error, or selective reporting.

The American Statistical Association explicitly warns that scientific conclusions should not be based only on whether a p value passes a threshold. The p value also depends on sample size, outcome variability, model assumptions, and the analysis chosen.[^asa]

Plain-language rule: Treat a p value as one diagnostic about compatibility with a model—not as a truth score for a claim.

Why a small p-value does not measure effect size

Statistical detectability depends on both the estimated effect and its standard error, so a very small effect can become statistically significant in a large, precise dataset. The reverse is also true: a larger estimate can remain non-significant in a small, noisy study.

Consider two transparent hypothetical comparisons:

• Study A: a biomarker changes by 0.2 units with a very narrow confidence interval and p<0.001.
• Study B: a patient-reported symptom score changes by 3 points, but the confidence interval is wide and p=0.08.

Study A supplies stronger evidence that its average biomarker difference is not zero under the model. It does not follow that 0.2 units is important. Study B is less statistically conclusive, but its interval may still include changes large enough to matter. The correct response is to inspect the estimates and intervals—not crown one study “real” and discard the other.

Clinical importance depends on the outcome, baseline risk, duration, burdens, adverse effects, and what magnitude would be meaningful in that population. There is no universal conversion from p value to patient benefit.

How should confidence intervals be read?

A confidence interval shows the estimate’s precision and the range of effect sizes reasonably compatible with the data under the analysis assumptions. Wider intervals mean more uncertainty; narrower intervals mean more precision.

For a difference measure, zero is often the no-difference value. For a ratio such as a risk ratio or hazard ratio, one is often the no-difference value. But simply checking whether the interval crosses that line throws away useful information.

Imagine a hypothetical peptide trial reports a mean between-group difference of 2 points with a 95% confidence interval from −1 to 5:

• the point estimate favors the peptide by 2 points;
• the interval includes no difference;
• it also includes a small disadvantage and a larger benefit;
• the result is therefore imprecise, not proof of no effect.

A frequentist 95% confidence interval should not be described as having a 95% probability of containing the true effect after this particular interval has been calculated. The 95% refers to the long-run performance of the interval procedure under its assumptions.[^greenland]

Better question: Does the interval exclude effects that would be meaningfully beneficial, meaningfully harmful, or both? That is more informative than asking only whether it crosses the null.

Absolute and relative differences can tell different stories

Relative measures describe proportional change; absolute measures show how many people or events separate the groups. Both are needed. Relative framing can make a modest absolute difference sound dramatic when the starting risk is low.

Suppose an event occurs in 2 of every 1,000 people in a comparison group and 1 of every 1,000 in a peptide group:

• relative risk reduction: 50%;
• absolute risk reduction: 1 event per 1,000 people, or 0.1 percentage points.

The 50% figure is mathematically correct, but incomplete without the denominators and time frame. Whether 1 fewer event per 1,000 matters depends on the event’s severity, treatment burden, adverse effects, uncertainty, and follow-up.

For continuous outcomes, ask for the raw between-group difference in interpretable units. A standardized effect can help compare scales, but it may conceal what changed in the original units. For time-to-event outcomes, a hazard ratio is not the same as an absolute probability at a particular time.

The Cochrane Handbook recommends presenting absolute effects alongside relative effects because baseline risk changes what the same relative estimate means in practice.[^cochrane]

What makes a result clinically important?

Clinical importance is a context judgment about outcome, magnitude, duration, tradeoffs, and patient relevance—not a second statistical threshold. It should be considered before results are known, not invented afterward to rescue a preferred finding.

Useful questions include:

1. Is the outcome patient-important? Survival, symptoms, function, quality of life, and serious adverse events usually speak more directly to patients than a laboratory marker.
2. How large is the absolute effect? Report the difference in understandable units and over a defined time.
3. Is it durable? A short-lived change may not support a long-term claim.
4. What are the burdens and harms? Benefit cannot be separated from adverse effects, monitoring, inconvenience, or uncertainty.
5. Was the threshold prespecified? A meaningful-change threshold chosen after seeing the data is vulnerable to spin.
6. Does the average hide heterogeneity? A mean effect may not describe every participant, but subgroup claims require their own credible evidence.

“Minimal clinically important difference” estimates can help when they are well validated for the specific outcome and population. They are not universal constants, and crossing one threshold does not automatically settle the benefit–harm question.

Why multiple testing increases false-positive risk

The more outcomes, doses, time points, subgroups, assays, and analyses researchers test, the more opportunities they have to obtain a small p value by chance. This is multiplicity.

Testing many endpoints creates more chances for an isolated positive result, while small groups can leave a confidence interval wide enough to include benefit, no difference, and harm.

If 20 independent null hypotheses are each tested at the 0.05 level, the chance of at least one false-positive result is about 64%: 1 − 0.95^20. Real analyses are often correlated, so that simple calculation is only an illustration, not a universal correction.

Credible studies address multiplicity through tools such as:

• a prespecified primary outcome;
• a testing hierarchy or gatekeeping procedure;
• adjusted significance thresholds;
• false-discovery-rate control for exploratory work;
• clear labels separating confirmatory from exploratory analyses.

The FDA’s multiple-endpoints guidance explains that a trial’s error rate can inflate when multiple endpoints are used to support effectiveness claims without appropriate control.[^fda-multiplicity] A nominally significant secondary endpoint does not automatically become confirmatory evidence when the prespecified hierarchy stopped earlier.

This is especially important in peptide research. An in-vitro paper may test several peptides, concentrations, cell lines, assays, and time points. An animal study may measure dozens of molecular and behavioral outcomes. One isolated p<0.05 result is less persuasive when the full testing universe is unclear.

Why a non-significant result is not proof of no effect

“Not statistically significant” means the analysis did not cross its chosen threshold; it does not mean the true effect is exactly zero. The result may be genuinely small, or the study may be too imprecise to distinguish among benefit, no difference, and harm.

Low power can arise from:

• too few participants or outcome events;
• high variability;
• substantial missing data;
• short follow-up;
• an effect smaller than the design anticipated;
• multiple-testing adjustments that require stronger evidence.

The confidence interval shows what the data failed to rule out. A narrow interval around no meaningful difference can be informative. A wide interval spanning substantial benefit and harm is unresolved.

This is why “absence of evidence” and “evidence of absence” are not interchangeable.[^altman]

Non-significance is also not proof of equivalence

Equivalence and non-inferiority require designs built to test specific margins. A conventional superiority test that fails to reject “no difference” does not establish that two interventions are equivalent.

To support equivalence, researchers generally prespecify a clinically justified equivalence margin and show that the confidence interval lies within it. To support non-inferiority, they prespecify a margin and analysis strategy appropriate to that question. Merely reporting p>0.05 does neither.

Non-significant safety results do not prove safety

Safety analyses are often underpowered for rare, delayed, or subgroup-specific harms. “No significant difference in adverse events” may coexist with very few events and wide uncertainty.

When reading peptide safety claims, check:

• event counts and denominators, not only percentages;
• confidence intervals for comparative risks;
• duration of exposure and follow-up;
• withdrawals and missing safety data;
• whether adverse events were actively collected and defined;
• whether the study was large enough to detect uncommon harms.

A study can fail to detect a safety signal without establishing that no clinically important risk exists.

Statistical significance does not establish causality

Causality comes from design, execution, assumptions, and corroborating evidence—not from the size of a p value. A precisely estimated association can still be biased.

Randomization can reduce confounding when allocation, follow-up, adherence, outcome measurement, and analysis are handled well. Observational studies may retain confounding, selection bias, misclassification, and time-related bias even when p values are tiny. Adjustment improves comparability only for variables measured and modeled adequately.

The same boundary applies across evidence levels:

• Human randomized evidence: prioritize the prespecified between-group effect, confidence interval, absolute outcomes, attrition, and patient-important endpoints.
• Human observational evidence: ask whether an association could reflect confounding, selection, exposure error, or outcome misclassification.
• Animal evidence: statistical significance remains model-level evidence; it does not remove translation limits involving species, dose, route, or endpoint.
• In-vitro evidence: a significant assay result shows a pattern under laboratory conditions, not a treatment effect in humans.

For a deeper bridge between models and human claims, see What Preclinical Actually Means. To assess whether an endpoint reflects real benefit, see Surrogate Endpoints vs Clinical Benefit.

How press releases and marketing can distort the result

Promotional summaries often lead with the most favorable statistical frame and omit the denominator, absolute effect, uncertainty, or testing plan. Common warning signs include:

• a large relative percentage with no absolute event rates;
• “significant improvement” with no effect size;
• “trend toward benefit” used to dress up a non-significant result;
• a secondary or subgroup result presented as though it were the primary outcome;
• a biomarker change presented as demonstrated clinical benefit;
• no mention of how many outcomes were tested;
• “no safety concerns” based on a small or short study.

Regulatory and reporting standards can require defined analyses and transparent presentation, but crossing a statistical decision threshold still does not prove that an effect is clinically meaningful for every patient. Reporting rules organize evidence; they do not replace judgment.

A 10-point checklist for reading a peptide study

A reliable reading starts with the research question and ends with relevance—not with the p value. Use this order:

1. Outcome: Was it a patient-important outcome, surrogate marker, animal behavior, or laboratory assay?
2. Comparator: Placebo, active treatment, untreated control, historical control, or no comparator?
3. Denominator: How many participants, samples, animals, and events actually contributed?
4. Effect size: What was the between-group difference in interpretable units?
5. Confidence interval: Which meaningful benefits and harms remain compatible with the data?
6. Absolute change: What changed per 100, 1,000, or a defined time period?
7. Prespecification: Was the endpoint and analysis declared before results were known?
8. Multiplicity: How many outcomes, groups, time points, and subgroups were tested, and how was error controlled?
9. Missing data: Who dropped out, why, and how were missing outcomes handled?
10. Patient relevance: Would the observed magnitude matter after considering duration, burdens, adverse effects, and evidence limits?

The companion guide How to Audit a Peptide Trial Registry Record shows how to compare published claims with prespecified endpoints and analysis plans.

The bottom line

Statistical significance is neither a verdict on truth nor a measure of importance. It is one component of evidence interpretation.

A defensible reading of a peptide study asks five separate questions:

1. What effect was estimated?
2. How precise was it?
3. Was the analysis prespecified and protected against multiplicity?
4. Does the study design support the causal claim being made?
5. Would the magnitude and outcome matter to patients?

Keeping those questions separate prevents two opposite errors: treating a small p value as proof, and treating a non-significant result as proof of no effect or safety.

Frequently asked questions

Does p<0.05 mean there is less than a 5% chance the result is random?

No. It means that, under the null hypothesis and analysis assumptions, the observed data or more extreme data would have a probability below 5%. It is not the probability that the result, hypothesis, or effect is “due to chance.”

Can a clinically trivial result be statistically significant?

Yes. Large samples can estimate very small differences precisely enough to produce small p values. Clinical importance still depends on magnitude, outcome, duration, baseline risk, harms, and burden.

Can a clinically important effect be non-significant?

Yes. A small or variable study may produce a wide confidence interval that includes both no difference and effects large enough to matter. That is uncertainty, not confirmation of benefit.

Does a confidence interval crossing zero mean there is no effect?

No. It means the interval includes the no-difference value. Read the full range to see whether meaningful benefit, meaningful harm, or both remain compatible with the data.

Is p=0.049 meaningfully different from p=0.051?

Usually not. The values are nearly identical measures of compatibility with the model, even though a mechanical threshold labels them differently. Estimates, intervals, design quality, and prior evidence should not change abruptly at 0.05.

Does a non-significant adverse-event comparison prove a peptide is safe?

No. Rare harms often require far larger samples and longer follow-up than efficacy outcomes. Event counts, intervals, exposure time, ascertainment, and missing data determine how reassuring the result can be.

---

This article is for general education and evidence literacy. It does not provide medical advice, treatment instructions, dosing guidance, or a recommendation to use any peptide.

Sources

[^asa]: Wasserstein RL, Lazar NA. The ASA’s Statement on p-Values: Context, Process, and Purpose. The American Statistician. 2016;70(2):129–133. doi:10.1080/00031305.2016.1154108 [^greenland]: Greenland S, Senn SJ, Rothman KJ, et al. Statistical tests, P values, confidence intervals, and power: a guide to misinterpretations. European Journal of Epidemiology. 2016;31:337–350. doi:10.1007/s10654-016-0149-3 [^altman]: Altman DG, Bland JM. Absence of evidence is not evidence of absence. BMJ. 1995;311:485. doi:10.1136/bmj.311.7003.485 [^fda-multiplicity]: U.S. Food and Drug Administration. Multiple Endpoints in Clinical Trials: Guidance for Industry. October 2022. FDA guidance [^cochrane]: Higgins JPT, Thomas J, Chandler J, et al., eds. Cochrane Handbook for Systematic Reviews of Interventions, Chapter 15: Interpreting results and drawing conclusions. Cochrane Training